Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2010

View Archived Issues

Pharming provides business update

D-156844 beneficial in mouse model of spinal muscular atrophy

Pharmacokinetics of HCV protease inhibitor ABT-450 assessed with and without ritonavir

Durable viral suppression seen with MK-7009 combination therapy in patients with hepatitis C

Targacept receives upfront payment from AstraZeneca

Vion files SPA with FDA for phase II/III trial of Onrigin in AML

FDA advisory committee recommends approval of Actelion's sNDA for Zavesca

Inverness offers to acquire up to 75.79% of Standard Diagnostics' issued shares

BioCryst signs agreements with Merck Serono and Hikma for antiviral peramivir

Sangamo initiates phase IIb trial of SB-509 in DN and phase I trial of CTL product in GM

Pfizer initiates phase II trial of SBI-087 in rheumatoid arthritis

Phase III Revlimid trial meets primary endpoint

Sumitomo describes HSc-025, effects in systemic sclerosis models

Protox Therapeutics presents phase IIb trial results on PRX-302 in BPH

Phase III studies show comparable efficacy with albinterferon alfa-2b vs. peginterferon alfa-2a

Antimitotic tubulin polymerization inhibitors disclosed by CNRS

Rockefeller University, SuperGen claim novel bacterial 2-epimerase inhibitors

Amira describes prostaglandin D receptor antagonists for respiratory disorders

Novel series of glucokinase activators presented by Takeda

Novel series of leukotriene synthesis inhibitors claimed by Biolipox

Nektar Therapeutics reports topline results from phase II trial of NKTR-102 in ovarian cancer

Vivus reported additional results from phase III REVIVE TA-301 study of avanafil for ED

ViroPharma and Sanquin sign agreement for hereditary angioedema drug Cinryze

Inovio and University of Pennsylvania expand license agreement for DNA vaccines

MAP not required to conduct second pivotal efficacy study for Levadex NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...